Kiniksa Pharma raises ARCALYST's 2025 sales forecast

Kiniksa Pharmaceuticals International

28/10/2025 11:41

Overview

Kiniksa Q3 2025 ARCALYST revenue grows 61% yr/yr to $180.9 mln

Company raises 2025 ARCALYST revenue guidance to $670-$675 mln

KPL-387 granted Orphan Drug Designation for pericarditis treatment

Outlook

Kiniksa raises 2025 ARCALYST revenue guidance to $670 mln - $675 mln

Company expects to remain cash flow positive annually

Data from KPL-387 Phase 2/3 trial expected in H2 2026

Result Drivers

ARCALYST ADOPTION - Increased adoption of ARCALYST for recurrent pericarditis drove significant revenue growth

REVENUE GUIDANCE RAISED - Kiniksa raised 2025 ARCALYST revenue guidance due to strong performance

ORPHAN DRUG DESIGNATION - KPL-387 granted Orphan Drug Designation for pericarditis treatment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$180.85 mln
Q3 EPS
$0.25
Q3 Net Income
$18.43 mln
Q3 Operating Expenses
$156.83 mln
Q3 Pretax Profit
$27.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $47.50, about 14.5% above its October 27 closing price of $40.60

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release: ID:nGNX4GcZj6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)